News & Events
Seres Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates (opens in a new tab)
– Data from Phase 3 study of SER-109 in recurrent C. difficile infection expected mid-2020; Potential to be the single pivotal study supporting product registration with the FDA – – Webcast SER-109 investor event to be held May 27 – – Conference call at 8:30 a.m. ET today – CAMBRIDGE, Mass.…
Rebiotix and Ferring Announce World’s First with Positive Preliminary Pivotal Phase 3 Data for Investigational Microbiome-based Therapy RBX2660 (opens in a new tab)
The post Rebiotix and Ferring Announce World’s First with Positive Preliminary Pivotal Phase 3 Data for Investigational Microbiome-based Therapy RBX2660 appeared first on Rebiotix.…
Seres Therapeutics to Host First Quarter 2020 Financial Results and Operational Progress Conference Call on May 7, 2020 (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Apr. 30, 2020– Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that management will host a conference call and live audio webcast on May 7, 2020 at 8:30 a.m. ET to discuss first quarter 2020 results and provide a general business update.…
Seres Therapeutics Appoints Lisa von Moltke, M.D., as Chief Medical Officer (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Apr. 6, 2020– Seres Therapeutics, Inc. , (Nasdaq: MCRB) today announced the appointment of Lisa von Moltke , M.D., FCP, as Executive Vice President and Chief Medical Officer. Dr. von Moltke joins Seres with an extensive career that includes senior leadership…
Seres Therapeutics Announces Completion of Enrollment in SER-109 Phase 3 ECOSPOR III Study for Recurrent Clostridium difficile Infection and Provides Clinical Pipeline Updates (opens in a new tab)
– Topline ECOSPOR III Phase 3 study data readout timing as planned for mid-2020 – – Potential for ECOSPOR III to be a single pivotal study supporting product registration with FDA – – Company assessing the impact of COVID-19 on SER-287, SER-401 and SER-301 clinical development programs –…
Seres Therapeutics Appoints Paul Biondi, Experienced Biopharmaceutical Strategy and Corporate Development Professional, to Its Board of Directors (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Mar. 23, 2020– Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Paul Biondi , Executive Partner at Flagship Pioneering, to its Board of Directors. Noubar Afeyan , Ph.D., a co-founder of Seres and Chief Executive Officer of Flagship…
Seres Therapeutics to Virtually Present at the Chardan Microbiome Medicines Summit (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)– Seres Therapeutics, Inc . (NASDAQ: MCRB) today announced that it will present at the virtual Chardan Microbiome Medicines Summit on Monday, March 16 at 8:15 a.m. ET . An audio webcast of the presentation will be available under the “Investors and Media” section…
Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration’s March 12, 2020 Safety Alert Related to Use of Fecal Microbiota Transplantation (opens in a new tab)
FDA alert is related to unapproved fecal microbiota transplantation (FMT) and does not impact Seres’ investigational microbiome therapeutic candidates CAMBRIDGE, Mass. –(BUSINESS WIRE)– Seres Therapeutics, Inc. (Nasdaq: MCRB) today provided a statement on a safety alert from the U.S.…
Seres Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Highlights (opens in a new tab)
– Data-rich period ahead including two expected late-stage microbiome clinical readouts: SER-109 in recurrent C. difficile infection in mid-2020 and SER-287 for ulcerative colitis in H2 2020 – – Clinical development activities initiated for SER-301, a next-generation, rationally designed product…
Seres Therapeutics to Present at the Cowen 2020 Health Care Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Feb. 25, 2020– Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced that it will present at the Cowen 2020 Health Care Conference in Boston, Mass. on Monday, March 2 at 1:30 p.m. ET . A live audio webcast of the presentation will be available under the…
Seres Therapeutics to Host Fourth Quarter 2019 Financial Results and Operational Progress Conference Call on March 2, 2020 (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Feb. 25, 2020– Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced that management will host a conference call and live audio webcast on March 2, 2020 at 8:30 a.m. ET to discuss fourth quarter and full year 2019 results and provide a general business update.…
Early airway microbial metagenomic and metabolomic signatures are associated with development of severe bronchopulmonary dysplasia (2018) (opens in a new tab)
The post Early airway microbial metagenomic and metabolomic signatures are associated with development of severe bronchopulmonary dysplasia (2018) appeared first on Alveolus Bio .…
Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660 (opens in a new tab)
Seres Therapeutics Appoints Stephen Berenson as Chairman of its Board of Directors (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Dec. 16, 2019– Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Stephen Berenson as Chairman of its Board of Directors. Roger Pomerantz , M.D., has decided to step down after serving as Chairman of the Board since 2013. Dr.…
Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate VE800 In Combination with Bristol-Myers Squibb’s Opdivo® (Nivolumab) (opens in a new tab)
Vedanta Biosciences Awarded $5.8 Million CARB-X Grant to Accelerate Development of VE707 for Multi-Drug Resistant Infections (opens in a new tab)
Vedanta Biosciences eligible for an additional $3.5 million upon completion of certain milestones Program addresses significant unmet therapeutic need for major hospital-acquired infections caused by multi-drug resistant organisms CAMBRIDGE, Mass., December 5, 2019 – Vedanta Biosciences, a clinical-stage biopharmaceuti…
Seres Therapeutics to Present at the Stifel 2019 Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Nov. 14, 2019– Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that it will present at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19 at 9:10 a.m. ET . A live audio webcast of the presentation will be available under the…
Vedanta Biosciences’ Silvia Caballero, Ph.D., Named to TIME 100 NEXT List for Innovative Leaders (opens in a new tab)
CAMBRIDGE, Mass., Nov. 13, 2019 – Vedanta Biosciences, a clinical-stage biopharmaceutical company developing a new category of therapies for immune-mediated diseases based on defined bacterial consortia, today announced that Silvia Caballero, Ph.D., who leads Vedanta’s program on multidrug-resistant organisms (MDRO), h…
Seres Therapeutics Reports Third Quarter Financial Results and Provides Business Update (opens in a new tab)
– Two late-stage microbiome clinical study readouts in ulcerative colitis and C. difficile infection anticipated in 2020 – – Debt facility secured, providing up to $50 million in additional capital; Corporate resources are expected to support operations into Q2 2021 – – Conference call at 8:30 a.m.…
Seres Therapeutics to Host Third Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on November 5, 2019 (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Oct. 31, 2019– Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that management will host a conference call and live audio webcast on November 5, 2019 at 8:30 a.m. ET to discuss third quarter 2019 results and provide a general business update.…